{
  "id": 6225492,
  "title": "Neurokinin 1 receptor blockade is associated with increased survival of patients with C. difficile infection",
  "url": "https://urgent.news/2026/09/07/neurokinin-1-receptor-blockade-is-associated-with-increased-survival",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-07T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.06.749186v1?rss=1"
  },
  "original_language": "en",
  "account": "Clostridioides difficile, a significant cause of healthcare-associated infections, leads to a toxin-mediated disease via the secretion of Toxin A and Toxin B. These toxins cause neurogenic inflammation, which contributes to intestinal inflammation in animal models. Substance P (SP), a vasoactive neuropeptide, is a key player in C. difficile toxin-induced inflammation. SP interacts with multiple receptors, including the high-affinity neurokinin-1 receptor (NK1-R) and lower-affinity receptors.\n\nIn vivo mouse infection models confirmed that SP's effects in hypervirulent C. difficile infections are largely mediated by NK1-R. Genetic mice lacking mast cells, which respond to SP in certain neurogenic inflammations, showed similar inflammation levels, indicating that mast cells are not crucial for C. difficile-induced inflammation. The researchers then investigated the role of NK1-R antagonists in a retrospective study of a large clinical cohort. After propensity matching, they found that NK1-R antagonists were associated with a significant survival benefit. Patients treated with these antagonists also displayed reduced vascular inflammation, as evidenced by increased serum albumin.\n\nThese findings suggest that blocking SP activity through NK1-R antagonism with small molecule inhibitors could be a valuable approach for adjunctive treatment during C. difficile infection.",
  "summary": "Clostridioides difficile is a major cause of healthcare associated infections. C. difficile infection (CDI) is a toxin-mediated disease driven by the secretion of two large protein toxins, Toxin A (TcdA) and Toxin B (TcdB). TcdA and TcdB cause neurogenic inflammation that can contribute to intestinal inflammation in rat and mouse models. Substance P (SP), a potent vasoactive neuropeptide, is a…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}